Search

New study results show Tradjenta® (linagliptin) reduces blood sugar in adults with type 2 diabetes at risk for kidney impairment

Boehringer Ingelheim and Lilly Partner with Duke Clinical Research Institute to Advance Multidisciplinary Care for People with Type 2 Diabetes and Cardiovascular Disease

Tackling Health Disparities and Inequities for Women With Heart Failure: New Program Encourages Black and Latina Women to Demand More From Their Care

Tackling Health Disparities and Inequities for Women with Heart Failure: New Program Encourages Black and Latina Women to Demand More From Their Care

FDA accepts sNDA for children/adolescents with fibrosing ILD

U.S. FDA accepts sNDA for OFEV® (nintedanib) for the potential treatment of children and adolescents aged 6-17 with fibrosing interstitial lung disease

Business Resource Groups at Boehringer Ingelheim

Business Resource Groups at Boehringer Ingelheim contribute to and help shape our company culture.

Survey reveals healthcare professionals believe greater collaboration is needed to improve patient outcomes in diabetes care

First Trials of Empagliflozin in Chronic Heart Failure | Boehringer Ingelheim US

Boehringer Ingelheim and Eli Lilly and Company today announced that the EMPEROR HF (heart failure) clinical trial program was initiated.

U.S. FDA approves first-in-class Glyxambi® (empagliflozin/linagliptin) tablets for adults with type 2 diabetes

First-in-class type 2 diabetes treatment Glyxambi® (empagliflozin/linagliptin) tablets for adults now available in U.S. pharmacies

FDA Approves Jardiance® (empaglifozin) for T2D | BI US

Read more about the approval of Boehringer Ingelheim's third product from the BI-Lilly Diabetes alliance, JARDIANCE, used to treat type-2 diabetes.

U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure

New type 2 diabetes treatment Jardiance® (empagliflozin) tablets for adults now available in U.S. pharmacies

US FDA approves Jardiance® (empagliflozin) to treat adults living with heart failure with reduced ejection fraction

New retrospective data showed empagliflozin reduced A1C, body weight and markers of abdominal fat in adults with type 2 diabetes

Jardiance® (empagliflozin) to be studied for the treatment of people with chronic heart failure

U.S. FDA Approves Once-daily Jentadueto® XR (linagliptin and metformin hydrochloride extended-release) Tablets for Adults with Type 2 Diabetes

New Swine Vaccine Combination Released | Boehringer Ingelheim US

Click here to read more on the introduction of another new swine vaccination combination from Boehringer Ingelheim, protecting pigs from common viruses.

Boehringer Ingelheim and Lilly announce the CAROLINA cardiovascular outcome trial of Tradjenta met its primary endpoint of non-inferiority compared with glimepiride

Jardiance® (empagliflozin) analysis reinforces established safety profile

Planting Trees to Help Care for the Environment

Onboarding

Updated real-world data show Gilotrif® followed by osimertinib provided a median overall survival of up to almost four years in patients with EGFR Del19 and T790M mutation-positive NSCLC

Life forward - Boehringer Ingelheim unveils its evolved company brand

FIBRONEER™ trials for IPF, other progressive fibrosing ILDs

Donald Zoz, M.D., Director and Senior Clinical Program Leader for Pulmonary Fibrosis, discusses the FIBRONEER™ global clinical program

First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers